ArticleJournal of neuro-oncology2020
Descriptive epidemiology of chordomas in the United States.
Article in Journal of neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Cervical chordomas: multicenter case series and meta-analysis.Journal of neuro-oncology · 2021Pooled it
- Review
- Incidence patterns and trends of chordoma in the United States: a population-based analysis of over 6,000 cases.Journal of bone oncology · 2026Article
- From Histology to Multi-Omics: Review of Chordoma Classification and Its Clinical Implications.Cells · 2026Review
- Metastatic sacral chordoma presenting as a cecal polyp: a case report.Journal of surgical case reports · 2025Article
- Unveiling Primary Bone Tumors of the Spine: A Review of Essential Imaging Clues.Diagnostics (Basel, Switzerland) · 2025Review
- Clival and paraclival pathologies: imaging features and differential diagnosis.Diagnostic and interventional radiology (Ankara, Turkey) · 2025Review
- Cervical chordoma en bloc resection and staged suprascapular nerve transfer reanimation: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- A refined treatment strategy for skull base chordoma: A protocol and management algorithm.Neurosurgical review · 2025Review
- Radiogenomics and radiomics of skull base chordoma: Classification of novel radiomic subgroups and prediction of genetic signatures and clinical outcomes.Neuro-oncology · 2025Article
- Selective targeting of TBXT with DARPins identifies regulatory networks and therapeutic vulnerabilities in chordoma.Science advances · 2025Article
- Resection of C2 chordoma after failed ion-beam radiotherapy: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- The Association of Gender in the Management and Prognosis of Vertebral and Sacral Chordoma: A SEER Analysis.Journal of clinical medicine · 2025Article
- Article
- Imaging of the skull base and orbital tumors.Japanese journal of radiology · 2025Review
- Unmasking Racial, Ethnic, and Socioeconomic Disparities in United States Chordoma Clinical Trials: Systematic Review.Cancers · 2025Review
- Endoscopic Endonasal Approach for Clival Chordomas in Elderly Patients: Clinical Characteristics, Patient Outcome, and Recurrence Rate.Journal of neurological surgery. Part B, Skull base · 2024Article
- Immunologic and Targeted Molecular Therapies for Chordomas: A Narrative Review.Journal of clinical medicine · 2024Review
- The Clinical Outcomes of Cervical Spine Chordoma: A Nationwide Multicenter Retrospective Study.Neurospine · 2024Article
- The impact of socioeconomic determinants on the access to care and survival in patients with spinal chordomas- a national cancer database analysis.Journal of neuro-oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeChordomas account for 1% to 4% of all bone malignancies and 0.5% of all primary intracranial central nervous system tumors. Prior epidemiologic literature is based on limited population data. The purpose of this study is to provide the largest and most inclusive population based study of the descriptive epidemiology of chordomas.
methodsThe Centers for Disease Control and Prevention and National Program of Cancer Registries were queried for chordoma in all locations. Age-adjusted incidence per 100,000 persons was calculated by age, sex, race, and ethnicity. Annual percentage change was calculated using Joinpoint.
resultsFrom 2004 to 2014, a total of 3670 chordomas were diagnosed in the US. The most common location was cranial (38.7%), followed by sacral (34.3%) and spinal (27.0%). The average age-adjusted incidence rate was 0.088 per 100,000 persons per year (95% CI 0.086-0.091), with an annual percentage change of 1.29% (95% CI 0.31-2.28%). For all chordomas, the incidence peaks in the 75-84 year age group. The male-to-female incidence rate ratio is 1.54 (p < 0.001). American Indian/Alaskan Native and Black patients had a statistically lower incidence rate than White and Asian/Pacific Islander patients.
conclusionApproximately 0.088 chordomas per 100,000 persons are newly diagnosed in the US each year, with cranial location being the most common, followed by sacral and spinal. Incidence increases with age, and men are at a significantly higher risk than women. This investigation represents the largest population-based epidemiologic study of chordomas in the US.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.